INC Research is a therapeutically focused global contract research organisation (CRO) with unrivaled expertise and a reputation for conducting global clinical development programs of the highest integrity.
Pharmaceutical and biotechnology companies look to INC Research for a complete range of customised Phase I – Phase IV programs in therapeutic areas of specialty, and in innovative pediatric trials. Our Trusted Process® methodology and therapeutic foresight leads our customers to more confident, better-informed drug and device development decisions.
Our mission is to help our customers bring products to market in order to improve world health. We invest in our customers’ success with proven therapeutic foresight and a trusted approach to advance drug and device development.
The company’s acquisition of the Phase II-IV operations (global clinical development) of MDS Pharma Services in July 2009 substantially deepened its outsourcing power to provide more geographic locations, therapeutic expertise, leadership and process excellence.
INC Research is headquartered in Raleigh, North Carolina, with nearly 2,000 employees and a presence in 40 countries worldwide. Its strong presence in North America; Western, Central and Eastern Europe; and India have been greatly enhanced by MDS GCD’s complementary presence in Western Europe and in the emerging markets of South America, the Asia-Pacific Rim and Africa.
With more global resources, INC Research offers first-hand regional knowledge and experience of cultural nuances and regulatory requirements. Sponsors benefit with an active investigator site database that provides more access to patients that meet specific study protocols.
3201 Beechleaf Court
Raleigh, NC 27604-1547